gdc-0973 and Skin-Diseases

gdc-0973 has been researched along with Skin-Diseases* in 5 studies

Reviews

1 review(s) available for gdc-0973 and Skin-Diseases

ArticleYear
Management of Treatment-Related Adverse Events with Agents Targeting the MAPK Pathway in Patients with Metastatic Melanoma.
    The oncologist, 2017, Volume: 22, Issue:7

    Tremendous progress has been made in the clinical landscape of advanced-stage. Targeted therapy with BRAF plus MEK inhibitors has become the standard of care for patients with advanced-stage

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azetidines; Benzimidazoles; Carbamates; Fever; Humans; Imidazoles; Indoles; Melanoma; Mitogen-Activated Protein Kinase Kinases; Oximes; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyridones; Pyrimidinones; Skin Diseases; Sulfonamides; Vemurafenib

2017

Other Studies

4 other study(ies) available for gdc-0973 and Skin-Diseases

ArticleYear
Progressive nodular histiocytosis in a 9-year-old boy treated with cobimetinib.
    Pediatric dermatology, 2022, Volume: 39, Issue:1

    Progressive nodular histiocytosis is a rare variant of non-Langerhans cell histiocytosis that affects the skin and mucous membranes and displays a progressive clinical course and poor response to treatment. We describe a case of severe progressive nodular histiocytosis harboring a KRAS p.G12S mutation in a 9-year-old boy, refractory to chemotherapy, who was successfully treated with the MEK inhibitor cobimetinib. This is the first report of the use of MEK inhibition for this histiocytosis subtype in a pediatric patient.

    Topics: Azetidines; Child; Histiocytosis; Histiocytosis, Langerhans-Cell; Humans; Male; Piperidines; Skin Diseases

2022
[Use of targeting therapy in Erdheim-Chester disease: A case report with neurologic involvement].
    La Revue de medecine interne, 2020, Volume: 41, Issue:6

    Erdheim-Chester disease (ECD) is a rare multisystemic disease characterised by an infiltration of various organs by CD68. We report the case of a 71-year-old woman with ECD which was revealed by neurological and cutaneous manifestations. The diagnosis was confirmed by skin biopsy and the BRAFV600E mutation was identified in skin tissue, leading to the use of combined therapy targeting the RAS-RAF-ERK-MEK pathway. This therapy allowed an improvement of cutaneous manifestations but neurological manifestations lead to death, underlying their notable severity.. Our case report shows the persistent diagnostic difficulty of the ECD and the particular gravity of neurologic involvement.

    Topics: Aged; Azetidines; Drug Therapy, Combination; Erdheim-Chester Disease; Female; Humans; Mitogen-Activated Protein Kinase Kinases; Molecular Targeted Therapy; Nervous System Diseases; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Rare Diseases; Skin Diseases; Vemurafenib

2020
Individualized treatment approaches for Langerhans cell histiocytosis.
    The British journal of dermatology, 2018, Volume: 178, Issue:6

    Topics: Adrenal Cortex Hormones; Adult; Aged, 80 and over; Azetidines; Bone Diseases; Dermatologic Agents; Female; Histiocytosis, Langerhans-Cell; Humans; Male; Middle Aged; Off-Label Use; Piperidines; Skin Diseases; Thalidomide

2018
Possible immune adverse events as predictors of durable response to BRAF inhibitors in patients with BRAF V600-mutant metastatic melanoma.
    European journal of cancer (Oxford, England : 1990), 2018, Volume: 101

    BRAF inhibitors (BRAFi) and MEK inhibitors (MEKi) are among the cornerstones of metastatic melanoma therapy demonstrating excellent response rates with duration of 7-12 m. Long-term benefit from these agents was reported in patients with normal lactate dehydrogenase (LDH) and less than three disease sites. However, a treatment-dependent marker for long-term efficacy is lacking. Data suggest that immune-related adverse events (irAEs) are associated with clinical benefit in patients treated with immunotherapy and that response to BRAF/MEK therapy may have an underlying immune mechanism. We hypothesised that AEs with an underlying immune mechanism may be associated with a durable response to targeted therapy. We retrospectively identified a cohort of 78 BRAF V600-mutant metastatic melanoma patients treated with BRAFi or BRAFi + MEKi between November 2010 and November 2013. Four treatment-related AEs including vitiligo, uveitis, erythema nodosum and keratitis sicca were defined as irAEs of interest. Retrospective analysis of AEs in relationship to progression-free survival (PFS), disease burden and LDH levels was performed. Median PFS (mPFS) for all patients was 7.5 months with responses ongoing in eight patients as of April 2017. Ten patients were identified with the AEs defined previously. Cox regression analysis revealed a very strong association between those AEs and PFS; mPFS was 42.8 m in patients with at least one AE versus 6.1 m in those without an AE (hazard ratio [HR] 0.22, p = 0.002). This association was independent of LDH levels and disease burden (HR 0.24, p = 0.035). This analysis demonstrates a strong association between immune AEs and durable response to targeted therapy and may provide a treatment-related biomarker to estimate the outcome of therapy.

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arthralgia; Azetidines; Female; Humans; Imidazoles; Kaplan-Meier Estimate; Male; MAP Kinase Kinase 1; Melanoma; Middle Aged; Mutation; Neoplasm Metastasis; Oximes; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyridones; Pyrimidinones; Retrospective Studies; Skin Diseases; Skin Neoplasms; Vemurafenib; Young Adult

2018